Brief: Fulcrum Therapeutics Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B Pioneer Trial Of Pociredir
24/02/2026 12:06
Feb 24 (Reuters) - Fulcrum Therapeutics Inc FULC.O :
* FULCRUM THERAPEUTICS ANNOUNCES POSITIVE 12-WEEK RESULTS
FROM THE
20 MG DOSE COHORT OF THE PHASE 1B PIONEER TRIAL OF POCIREDIR IN
SICKLE CELL DISEASE
* FULCRUM THERAPEUTICS INC - POCIRDIR WELL-TOLERATED WITH NO
TREATMENT-RELATED SERIOUS ADVERSE EVENTS
Source text: ID:nGNX1Nswmk
Further company coverage: FULC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fulcrum Therapeutics
See all newsFulcrum down after announcing restructuring, plans to cut 85% jobs
Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Fulcrum falls after discontinuing sickle cell drug program